Alumis

Alumis is a biotechnology company in Phase III clinical trials, dedicated to developing kinase inhibitors for the treatment of immune-mediated diseases. Alumis Inc. is pioneering a precision approach, leveraging insights gained from robust data analysis to select the right targets, the right molecules, the right indications, the right patients, and the right endpoints, thereby delivering optimal outcomes for patients. Alumis believes that combining the company’s insights with an integrated approach to drug development will yield next-generation treatments for immune dysfunction. Alumis was incubated by Foresite Labs and is led by a team of seasoned professionals committed to transforming the lives of patients with immune-mediated diseases through the development of a range of transformative therapies.